Oncology

News

FDA turns down MSD, Daiichi Sankyo HER3 ADC for lung cancer

The FDA has said it cannot approve MSD and Daiichi Sankyo’s HER3-targeted antibody-drug conjugate (ADC) patritumab deruxtecan because of problems at a third-party manufacturer.

News

Imfinzi fails lung cancer trial, but scores in bladder cance...

AstraZeneca’s hopes of positioning its PD-L1 inhibitor Imfinzi as a post-surgery therapy for people with earlier-stage lung cancer have taken a knock, although it performed well in a bladde

News

Merck cans head and neck cancer drug once hailed as big hope

Two years ago, Merck KgAA was talking up xevinapant as a leap forward in head and neck cancer and one of the brightest stars in its late-stage pipeline, Now, the drug has been abandoned aft

News

Daiichi Sankyo’s Ezharmia cleared in Japan for rare lymphoma

Daiichi Sankyo has a second approval in Japan for Ezharmia, its first-in-class dual EZH1 and EZH2 inhibitor, as a treatment for relapsed or refractory peripheral T-cell lymphoma (PTCL).

News

BMS gets FDA approval for Krazati in colorectal cancer

Bristol-Myers Squibb’s KRAS inhibitor Krazati has been approved for a second indication, colorectal cancer (CRC), which could inject some much-needed sales growth into the product.

Oncology

ASCO 2024 - Scot Ebbinghaus

Merck & Co (MSD outside the United States) celebrated the tenth anniversary of the first Keytruda approval at ASCO this year, but the company isn’t resting on its laurels.

FDA turns down MSD, Daiichi Sankyo HER3 ADC for lung cancer

Imfinzi fails lung cancer trial, but scores in bladder cance...

Merck cans head and neck cancer drug once hailed as big hope

Daiichi Sankyo’s Ezharmia cleared in Japan for rare lymphoma

BMS gets FDA approval for Krazati in colorectal cancer

ASCO 2024 - Scot Ebbinghaus

An AI supercomputer and discovering next-gen brain disorder ...

How to meet your physicians where they are online

Oncology

Editor's Picks